PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate CancerCheng Wu, Timothy C. Thompson, Shan Peng et al.|Molecular Cancer Therapeutics|2021Cited by 58
Restoration of tissue factor pathway inhibitor inhibits invasion and tumor growth in vitro and in vivo in a malignant meningioma cell lineShakuntala Kondraganti, William Olivero|International Journal of Oncology|2006Cited by 44
RNAi-mediated downregulation of urokinase plasminogen activator and its receptor in human meningioma cells inhibits tumor invasion and growthShakuntala Kondraganti, William C. Olivero|International Journal of Oncology|2006Cited by 39
SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth SuppressionChuandong Geng, Timothy C. Thompson, Man-Chao Zhang et al.|Clinical Cancer Research|2023Cited by 24
Supplementary Figure S13 from SPOP Mutations Target STING1 Signaling in Prostate Cancer and Create Therapeutic Vulnerabilities to PARP Inhibitor–Induced Growth SuppressionChuandong Geng, Timothy C. Thompson, Man-Chao Zhang et al.|Unknown|2023Cited by 0